[1]
Gordon BA, Blazey T, Su Y, et al. Longitudinal beta-amyloid deposition and hippocampal volume in preclinical alzheimer disease and suspected non-alzheimer disease pathophysiology. JAMA Neurol 2016; 73(10): 1192-200.
[2]
Frisoni GB, Winblad B, O’Brien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer’s disease: A step forward but not yet ready for widespread clinical use. Int Psychogeriatr 2011; 23(8): 1191-6.
[3]
Krell-Roesch J, Ruider H, Lowe VJ, et al. FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Alzheimers Dis 2016; 53(4): 1609-16.
[4]
Burke SL, Maramaldi P, Cadet T, et al. Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer’s disease: Dementia. Int Psychogeriatr 2016; 28(9): 1409-24.
[5]
Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013; 70(5): 587-93.
[6]
Elbaz A. Prodromal symptoms of Parkinson’s disease: Implications for epidemiological studies of disease etiology. Rev Neurol (Paris) 2016; 172(8-9): 503-11.
[7]
Barnes DE, Yaffe K, Byers AL, et al. Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012; 69(5): 493-8.
[8]
Postuma R, Daniela B, Matthew S, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30(12): 1591-601.
[9]
Chiba Y, Fujishiro H, Iseki E, et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: Comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord 2012; 33(4): 273-81.
[10]
Ganesh MB, Nupur G, Denise H, et al. Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry 2016; 24(11): 1095.
[11]
Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: Pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27(5): 617-26.
[12]
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology 2018; 90(3): 126-35.
[13]
Whalley LJ, Dick FD, McNeill G, et al. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 2006; 5(1): 87-96.
[14]
Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016; 12(2): 195-202.
[15]
Clelia P, Dario B, Vincenzo P, et al. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr Dis Treat 2007; 3(1): 145-52.
[16]
Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol 2015; 14(1): 57-64.
[17]
Takizawa C, Thompson PL, van Walsem A, et al. Epidemiological and economic burden of Alzheimer’s disease: A systematic literature review of data across Europe and the United States of America. J Alzheimers Dis 2015; 43(4): 1271-84.
[18]
Snyder HM, Hendrix J, Bain LJ, et al. Alzheimer’s disease research in the context of the national plan to address Alzheimer’s disease. Mol Aspects Med 2015; 43-44: 16-24.
[19]
Broderick JE, DeWitt EM, Rothrock N, et al. Advances in Patient-Reported Outcomes: The NIH PROMIS((R)) Measures. EGEMS (Wash DC) 2013; 1(1): 1015. p
[20]
Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. J Am Soc Anesthesiol 2008; 108(5): 822-30.
[21]
Ezzati A, Jiang J, Katz MJ, et al. Validation of the perceived stress scale in a community sample of older adults. Int J Geriatr Psychiatry 2014; 29(6): 645-52.
[22]
Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord 2016; 190: 264-71.
[23]
Golimstok A, Rojas J, Romano M, et al. Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: A case-control study. Eur J Neurol 2011; 18(1): 78-84.
[24]
Lee HM, Koh SB. Many Faces of Parkinson’s disease: Non-motor symptoms of Parkinson’s disease. J Mov Disord 2015; 8(2): 92-7.
[25]
Seifan A, Assuras S, Huey ED, et al. Childhood learning disabilities and atypical dementia: A retrospective chart review. PLoS One 2015; 10(6): e0129919.
[26]
Cockrell J, Folstein M. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988; 24(4): 689.
[27]
Mack WJ, Freed DM, Williams BW, et al. Boston Naming Test: shortened versions for use in Alzheimer’s disease. J Gerontol 1992; 47(3): 154-P8.
[28]
Tombaugh TN. Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol 2004; 19(2): 203-14.
[29]
Schmidt M. Rey auditory verbal learning test: A handbook 1996:
Western Psychological Services Los Angeles, CA
[30]
Weintraub S, Dikmen SS, Heaton RK, et al. The cognition battery of the NIH toolbox for assessment of neurological and behavioral function: Validation in an adult sample. J Int Neuropsychol Soc 2014; 20(6): 567-78.
[31]
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 65(12): 1863-72.
[32]
Alberta MS, Steven TD, Dennis D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 270-9.
[33]
McKhann GM, David SK, Howard C. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9.
[34]
Gomperts SN. Lewy body dementias: Dementia with lewy bodies
and parkinson disease dementia. Continuum (Minneap Minn),
2016. 22(2 Dementia): p. 435-63.
[35]
Szeto JY, Mowszowski L, Gilat M, et al. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(1): 31-5.
[36]
Seifan A, Schelke M, Obeng-Aduasare Y, et al. Early life epidemiology of Alzheimer’s disease-a critical review. Neuroepidemiology 2015; 45(4): 237-54.
[37]
Maria TP, Riccardo S, Marcello M, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: A 4-year follow-up study. J Neural Transm (Vienna) 2016; 123(12): 1399-402.
[38]
Delgado‐Alvarado M, Belén G, Navalpotro‐Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 2016; 31(6): 861-81.
[39]
Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease: A longitudinal analysis. Neurology 2015; 84(6): 617-22.
[40]
Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75(6): 494-9.
[41]
Bensamoun D, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis 2015; 49(2): 387-98.
[42]
Danna J, Andrew S, Matthew S, et al. Imaging prodromal Parkinson disease: The parkinson associated risk syndrome study. Neurology 2014; 83(19): 1739-46.
[43]
Edmonds EC, Delano-Wood L, Clark LR, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 2015; 11(4): 415-24.
[44]
Edmonds EC, Delano-Wood L, Jak AJ, et al. “Missed” mild cognitive impairment: High false-negative error rate based on conventional diagnostic criteria. J Alzheimers Dis 2016; 52(2): 685-91.
[45]
Seifan A, Isaacson RI. The Alzheimer’s prevention clinic at weill cornell medicine: Risk stratification and early intervention. J Prev Alzheimers Dis 2015; 2(4): 254-66.
[46]
Vos SJB, Gordon BA, Su Y, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 2016; 44: 1-8.
[47]
Tiia N, Jenni L, Alina S, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 2015; 385(9984): 2255-63.
[48]
Sevigny J. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 2016; 537(7618): 50-6.